$23.79
0.10.42%
After Hours: 8:49 AM EDT
15 minutes delayed
Dianthus Therapeutics
DNTHNASDAQ
Dianthus Therapeutics (NASDAQ:DNTH) Stock, Analyst Ratings, Price Targets, Predictions
Dianthus Therapeutics Inc has a consensus price target of $35.33, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and Raymond James on May 16, 2024, May 10, 2024, and April 18, 2024. With an average price target of $43 between HC Wainwright & Co., Wedbush, and Raymond James, there's an implied 72.97% upside for Dianthus Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Wedbush
Raymond James
Jefferies
1calculated from analyst ratings
Analyst Ratings for Dianthus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos | — | Initiates | → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 60.9% | HC Wainwright & Co. | Swayampakula Ramakanth | → $40 | Initiates | → Buy | Get Alert |
| 05/10/2024 | Buy Now | 52.86% | Wedbush | Laura Chico | $33 → $38 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | 105.15% | Raymond James | Steven Seedhouse | $34 → $51 | Maintains | Outperform | Get Alert |
| 03/22/2024 | Buy Now | 56.88% | Jefferies | Maury Raycroft | $22 → $39 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | 32.74% | Wedbush | Laura Chico | $24 → $33 | Maintains | Outperform | Get Alert |
| 02/15/2024 | Buy Now | 76.99% | Stifel | Alex Thompson | → $44 | Initiates | → Buy | Get Alert |
| 01/26/2024 | Buy Now | -3.46% | Wedbush | Laura Chico | $23 → $24 | Maintains | Outperform | Get Alert |
| 12/26/2023 | Buy Now | -11.5% | Jefferies | Maury Raycroft | → $22 | Initiates | → Buy | Get Alert |
| 11/22/2023 | Buy Now | -7.48% | Wedbush | Laura Chico | → $23 | Initiates | → Outperform | Get Alert |
| 09/28/2023 | Buy Now | -3.46% | Raymond James | Steven Seedhouse | → $24 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Dianthus Therapeutics (DNTH) stock?
The latest price target for Dianthus Therapeutics (NASDAQ:DNTH) was reported by Cantor Fitzgerald on June 27, 2024. The analyst firm set a price target for $0.00 expecting DNTH to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dianthus Therapeutics (DNTH)?
The latest analyst rating for Dianthus Therapeutics (NASDAQ:DNTH) was provided by Cantor Fitzgerald, and Dianthus Therapeutics initiated their overweight rating.
When was the last upgrade for Dianthus Therapeutics (DNTH)?
There is no last upgrade for Dianthus Therapeutics
When was the last downgrade for Dianthus Therapeutics (DNTH)?
There is no last downgrade for Dianthus Therapeutics.
When is the next analyst rating going to be posted or updated for Dianthus Therapeutics (DNTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dianthus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dianthus Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Dianthus Therapeutics (DNTH) correct?
While ratings are subjective and will change, the latest Dianthus Therapeutics (DNTH) rating was a initiated with a price target of $0.00 to $0.00. The current price Dianthus Therapeutics (DNTH) is trading at is $24.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.